… and if it is confirmed through human trials that knockdown of FTO with Bisantrene reduces resistance to PD-1 therapy then Bisantrene could achieve revenues as much as Keytruda ( whilst also having an effect where increase in use and hence sales of Keytruda causes increase in sales of Bisantrene ).
See last point below.
![]()
- Forums
- ASX - By Stock
- RAC
- Understanding RAC
Understanding RAC, page-34
-
- There are more pages in this discussion • 8 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RAC (ASX) to my watchlist
|
|||||
Last
$1.79 |
Change
0.040(2.29%) |
Mkt cap ! $298.0M |
Open | High | Low | Value | Volume |
$1.82 | $1.82 | $1.79 | $17.21K | 9.606K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 2730 | $1.78 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.80 | 2111 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 226 | 1.790 |
2 | 4545 | 1.755 |
1 | 9998 | 1.750 |
1 | 1100 | 1.745 |
1 | 1100 | 1.735 |
Price($) | Vol. | No. |
---|---|---|
1.800 | 767 | 1 |
1.815 | 8488 | 1 |
1.820 | 2000 | 1 |
1.825 | 2339 | 1 |
1.830 | 45619 | 3 |
Last trade - 10.14am 10/07/2024 (20 minute delay) ? |
Featured News
RAC (ASX) Chart |
The Watchlist
I88
INFINI RESOURCES LIMITED
Charles Armstrong, CEO
Charles Armstrong
CEO
SPONSORED BY The Market Online